New antibiotics could be designed by discovering the mechanism a weapon bacteria uses to vanquish their competitors.
List view / Grid view
Filter the results
Molecules that are critical for T cells to travel to and populate the lungs have been identified which could strengthen vaccines against influenza.
A mechanism has been identified which regulates the release of insulin from β-cells and could be used to develop new treatments for type 2 diabetes.
A new target has been identified for the treatment of heart failure, heart attack, stroke and neurodegeneration.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
Researchers discover that a non-coding region of the genome originates a key molecule for the proliferation of cancerous tumours.
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
New approach restores epithelial function in diarrhoea and inflammatory bowel disease models...
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
Scientists discover new genes and biological pathways linked to osteoarthritis, which could help identify starting points for new medicines...
Researchers have identified a tiny hidden pocket on the NMDA receptor that could be targeted to treat strokes and seizures...
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Application note: A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.